share_log

Bausch Health Companies Inc.'s (NYSE:BHC) Path To Profitability

Bausch Health Companies Inc.'s (NYSE:BHC) Path To Profitability

bausch health公司(纽交所:BHC)的盈利之路
Simply Wall St ·  11/08 13:17

Bausch Health Companies Inc. (NYSE:BHC) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. The US$3.5b market-cap company posted a loss in its most recent financial year of US$592m and a latest trailing-twelve-month loss of US$178m shrinking the gap between loss and breakeven. The most pressing concern for investors is Bausch Health Companies' path to profitability – when will it breakeven? Below we will provide a high-level summary of the industry analysts' expectations for the company.

Bausch Health Companies Inc.(纽约证券交易所代码:BHC)的业务可能即将取得重大成就,因此我们想对该公司有所了解。Bausch Health Companies Inc. 是一家多元化的专业制药和医疗器械公司,在美国和国际上运营。这家市值为35亿美元的公司公布其最近一个财政年度的亏损为5.92亿美元,最近十二个月的亏损为1.78亿美元,缩小了亏损与盈亏平衡之间的差距。投资者最紧迫的担忧是Bausch Health Companies的盈利之路——它何时会实现盈亏平衡?下面,我们将概述行业分析师对公司的期望。

Bausch Health Companies is bordering on breakeven, according to the 7 American Pharmaceuticals analysts. They expect the company to post a final loss in 2024, before turning a profit of US$405m in 2025. The company is therefore projected to breakeven just over a year from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 218%, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

根据7位美国制药分析师的说法,Bausch Health Companies已接近盈亏平衡。他们预计,该公司将在2024年公布最终亏损,然后在2025年实现4.05亿美元的盈利。因此,预计该公司将在一年多后实现盈亏平衡。为了在这一天实现盈亏平衡,公司必须同比增长多少?使用最适合的线,我们计算出平均年增长率为218%,非常活跃。如果事实证明这个利率过于激进,该公司的盈利时间可能比分析师预测的要晚得多。

big
NYSE:BHC Earnings Per Share Growth November 8th 2024
纽约证券交易所:BHC 每股收益增长 2024 年 11 月 8 日

We're not going to go through company-specific developments for Bausch Health Companies given that this is a high-level summary, though, keep in mind that typically pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

鉴于这是一份高层次的摘要,我们不打算详细介绍Bausch Health Companies的公司具体发展情况,但请记住,通常药品的现金流周期会不规律,具体取决于产品开发阶段。因此,高增长率并非不寻常,尤其是在公司处于投资期时。

Before we wrap up, there's one issue worth mentioning. Bausch Health Companies currently has negative equity on its balance sheet. Accounting methods used to deal with losses accumulated over time can cause this to occur. This is because liabilities are carried forward into the future until it cancels. These losses tend to occur only on paper, however, in other cases it can be forewarning.

在我们总结之前,有一个问题值得一提。Bausch Health Companies目前的资产负债表上有负资产。用于处理一段时间内累积的损失的会计方法可能会导致这种情况的发生。这是因为负债会结转到未来,直到注销。这些损失往往只发生在纸面上,但是,在其他情况下,这可能是预先警告。

Next Steps:

后续步骤:

There are too many aspects of Bausch Health Companies to cover in one brief article, but the key fundamentals for the company can all be found in one place – Bausch Health Companies' company page on Simply Wall St. We've also compiled a list of key factors you should further examine:

Bausch Health Companies的很多方面都无法在一篇简短的文章中介绍,但该公司的关键基本面都可以在一个地方找到——Bausch Health Companies在Simply Wall St的公司页面。我们还整理了一份关键因素清单,你应该进一步研究:

  1. Valuation: What is Bausch Health Companies worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Bausch Health Companies is currently mispriced by the market.
  2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Bausch Health Companies's board and the CEO's background.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
  1. 估值:Bausch Health Companies今天的价值是多少?价格中是否已经考虑了未来的增长潜力?我们的免费研究报告中的内在价值信息图有助于可视化Bausch Health Companies目前是否被市场错误定价。
  2. 管理团队:由经验丰富的管理团队掌舵增强了我们对业务的信心——看看谁是Bausch Health Companies董事会成员以及首席执行官的背景。
  3. 其他表现优异的股票:还有其他股票可以提供更好的前景并有良好的往绩记录吗?在这里浏览我们免费列出的这些优质股票。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?担心内容吗?直接联系我们。或者,发送电子邮件给编辑组(网址为)simplywallst.com。
Simply Wall St 的这篇文章本质上是笼统的。我们仅使用公正的方法提供基于历史数据和分析师预测的评论,我们的文章并非旨在提供财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不会考虑最新的价格敏感型公司公告或定性材料。华尔街只是没有持有上述任何股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发